亞太地區(qū)腫瘤專(zhuān)家小組《德曲妥珠單抗相關(guān)不良反應(yīng)的監(jiān)測(cè)和管理指南》解讀
Interpretation of "Guidelines for Monitoring and Management of Adverse Reactions Associated with Trastuzumab" issued by the Asia-Pacific Oncology Expert Group
TANG Xueqin,ZHENG Xueyan,WANG Qiaoling,LIU Li,LI Ben*Chongqing Health Center for Women and Children/Women and Children′s Hospital of Chongqing Medical University,Chongqing 401147 China*Corresponding Author LI Ben,E-mail:2019111189@stu.cqmu.edu.cn
Abstract This article interpreted "Guidelines for Monitoring and Management of Adverse Reactions Associated with Trastuzumab" issued by the Asia-Pacific Oncology Expert Group in August 2023.It aimed to provide practical suggestions for clinical medical staff to monitor and manage adverse events associated with trastuzumab.
Keywords breast cancer;trastuzumab deruxtecan;adverse reactions;human epidermal growth factor receptor 2;targeted therapy;nursing
摘要 對(duì)2023年8月亞太地區(qū)腫瘤專(zhuān)家小組發(fā)布的《德曲妥珠單抗相關(guān)不良反應(yīng)的監(jiān)測(cè)和管理指南》進(jìn)行解讀,旨在為臨床醫(yī)務(wù)人員監(jiān)測(cè)和管理德曲妥珠單抗相關(guān)不良事件提供實(shí)用建議。(剩余15738字)